Historical Archive of Blood Pressure and Evolution of Hypertension
Abstract
Blood pressure is the pressure of the blood within the arteries of the circulatory system. The pulse is the feeling of the heartbeat in some arteries. Hypertension also known as high blood pressure, is the name given to a common medical condition in which the force exerted by the blood carried from the heart to the body against the walls of the arteries is high enough to cause health problems such as heart disease. Hypertension has been known since antiquity. Descriptions have been found in the Egyptian papyri, in ancient Chinese and Indian medical literature, as well as, in the work of ancient Greek physicians such as Galen and Hippocrates and Muslim scientists into Latin in Andalusia and Sicily. When we come to the 17th century, we see that blood circulation was experimentally proven by William Harvey. The important work of the 18th century, blood pressure was first recognized and first attempts were made to measure this pressure. The clinical sphygmomanometer that could measure systolic pressure over the radial artery is defined by Samuel von Basch in 1880. 20th century has witnessed changes in terminology, discovery of the measurement method that is recently used and emergence of pathogenetic definitions and by the middle of the twentieth century, checking BP by sphygmomanometer became part of the routine physical examination in hospitals and clinics. It was considered necessary to treat hypertension after the detrimental effects of high blood pressure on the body were noticed. So reserpine, hydralazine, ganglion blocking agents, peripheral adrenergic inhibitor, oral diuretics, beta blocker, ACE inhibitors, calcium channel blockers drugs such as were synthesized. While the use of some drugs is limited due to their side effects, some are still used in the treatment of hypertension today. Additionally the potential for gene therapy in hypertension is one that will be watched with interest.The search for new antihypertensive drugs are still ongoing. The potential for gene therapy in hypertension is one that will be watched with interest.
Keywords: History of blood pressure, pulse, hypertension, antihypertensive drugs
Keywords:
History of blood pressure, pulse, hypertension, antihypertensive drugsDOI
https://doi.org/10.22270/jddt.v12i3.5333References
Wakerlin GE. From Bright toward light: the story of hypertension research. Circulation Research (1962) XI: 131-136. https://doi.org/10.1161/01.RES.11.1.131
Esunge PM. From blood pressure to hypertension: the history of research. J R Soc Med 1991; 84: 621.
Heydari M, Dalfardi B, Golzari SE, Habibi H, Zarshenas MM. The medieval origins of the concept of hypertension. Heart Views. 2014; 15(3): 96-8. https://doi.org/10.4103/1995-705X.144807
Matini J. Hidayat al-Mutaallimin Fi al-Tibb (A Guide to Medical Students) by Abubakr Rabi-ibn Ahmad Akhawayni Bukhari [in Persian] Mashhad: Mashhad University Press; 1965. pp. 181-8.
Rodriguez MA, Kumar SK, De Caro M. Hypertensive crisis. Cardiol Rev. 2010; 18: 102-7. https://doi.org/10.1097/CRD.0b013e3181c307b7
Pellegrini G. The scientific work of Scipione Riva-Rocci. Minerva Med. 1964; 55: 900-3.
Cameron JS, Hicks J. Frederick Akbar Mahomed and his role in the description of hypertension at Guy's Hospital. Kidney Int 1996; 49:1488-506. https://doi.org/10.1038/ki.1996.209
O'Rourke MF. Frederic Akbar Mahomed. Hypertension 1992; 19:212-7. https://doi.org/10.1161/01.HYP.19.2.212
O'Brien E. Theodore Caldwell Janeway (1872-1917): the quest for precision. J Hum Hypertens. 1996; 10(8): 501-4.
Booth J. A short history of blood pressure measurement. Proc Roy Soc Med 1977; 70:793-9. https://doi.org/10.1177/003591577707001112
Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension, I: the production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934; 59: 347-79. https://doi.org/10.1084/jem.59.3.347
Page IH, Helmer OM. A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. Exp Med 1940; 71: 29-42. https://doi.org/10.1084/jem.71.1.29
Braun-Menéndez E, Fasciolo JC, Leloir LF, Muñoz JM. The substance causing renal hypertension. J Physiol 1940; 98: 283-98. https://doi.org/10.1113/jphysiol.1940.sp003850
Mohammad G. Saklayen, Neeraj V. Deshpande. Timeline of History of Hypertension Treatment. Front Cardiovasc Med. (2016) 3: 3. https://doi.org/10.3389/fcvm.2016.00003
Moser M. Evolution of the treatment of hypertension from the 1940s to JNC V. Am J Hypertens. 1997; 10(3):2S-8S. https://doi.org/10.1016/S0895-7061(97)00016-2
Moyer JH, Heider C, Pevey K, Ford RV.The effect of treatment on the vascular deterioration associated with hypertension, with particular emphasis on renal function. Am J Med 1958; 24:177. https://doi.org/10.1016/0002-9343(58)90306-1
Sjoerdsma A. Chemotherapy of hypertension: yesterday-today-tomorrow? Circulation 1963; 28: 161. https://doi.org/10.1161/01.CIR.28.2.161
Freis ED, Wanko A, Wilson IM, Parrish AE. Treatment of essential hypertension with chlorothiazide (diuril); its use alone and combined with other antihypertensive agents. JAMA 1958; 166:137-40. https://doi.org/10.1001/jama.1958.02990020025004
Guyton AC. Blood pressure control-special role of kidneys and body fluid. Science 1991; 252:1813-6. https://doi.org/10.1126/science.2063193
Jillian G. Baker, Stephen J. Hill, Roger J. Summers. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci. 2011; 32(4-2):227-234. https://doi.org/10.1016/j.tips.2011.02.010
Black J.W. Comparison of some properties of pronethalol and propranolol. Br. J. Pharmacol. Chemother. 1965; 25:577-591. https://doi.org/10.1111/j.1476-5381.1965.tb01782.x
Veterans Administration Cooperative Study Group on Anti-hypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967; 202:1028-34. https://doi.org/10.1001/jama.202.11.1028
Gregory Y.H. Lip. Comprehensive Hypertension. Mosby Elsevier, 2007.
Ferreıra SH. A Bradykının-Potentıatıng Factor (BPF) Present in the Venom of Bothrops Jararca. Br J Pharmacol Chemother 1965; 24:163-9. https://doi.org/10.1111/j.1476-5381.1965.tb02091.x
Ng KK, Vane JR. Conversion of angiotensin I to angiotensin II. Nature 1967; 216(5117):762-6. https://doi.org/10.1038/216762a0
Godfraind T. Discovery and Development of Calcium Channel Blockers. Front Pharmacol. 2017; 8:286. https://doi.org/10.3389/fphar.2017.00286
Fleckenstein A. History of calcium antagonists. Circ Res. 1983; 52(2 Pt2):I3-16.
Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000; 355(9204):637-45. https://doi.org/10.1016/S0140-6736(99)10365-9
Adam M. Integrating research and development: the emergence of rational drug design in the pharmaceutical industry. Stud Hist Philos Biol Biomed Sci. 2005; 36(3):513-37. https://doi.org/10.1016/j.shpsc.2005.07.003
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertension and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288:2981-97. https://doi.org/10.1001/jama.288.23.2981
Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethazide as required, in the Anglo Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. https://doi.org/10.1016/S0140-6736(05)67185-1
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23):2417-28. https://doi.org/10.1056/NEJMoa0806182
Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, et al. Macrophage regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009; 15:545-52. https://doi.org/10.1038/nm.1960
Machnik A, Dahlmann A, Kopp C, Goss J, Wagner H, van Rooijen N, et al. Mononuclear phagocyte system depletion blocks interstitial tonicity-¬responsive enhancer binding protein/vascular endothelial growth factor C expression and induces salt-sensitive hypertension in rats. Hypertension 2011; 55:755-61 https://doi.org/10.1161/HYPERTENSIONAHA.109.143339
Pober JS. Is hypertension an autoimmune disease? J Clin Invest 2014; 124:4234-6. https://doi.org/10.1172/JCI77766
Guzik TJ, Mikolajczyk T. In search of the T cell involved in hypertension and target organ damage. Hypertension 2014; 64:224-6. https://doi.org/10.1161/HYPERTENSIONAHA.114.03340
Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension 2015; 65:1331-40. https://doi.org/10.1161/HYPERTENSIONAHA.115.05315
Published



How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).